Samsung Biologics is acquiring the PolyPeptide Group, with the deal valued at 2.7 trillion won, or approximately $1.8 billion. The acquisition is an all-cash offer and is expected to expand Samsung Biologics' global network. The move appears to be part of the company's strategy to accelerate its multi-modality approach, with PolyPeptide Group being a Swiss contract development and manufacturing organization specializing in peptides.